Resumo
BACKGROUND: In Brazil, the prophylaxis of influenza with the antivirals oseltamivir and zanamivir is cost-effective and recommended for the groups with higher risk of complications. In this study we estimated the impact of the chemoprophylaxis in the health system budget from 2017 to 2023. METHODS: We calculated the size of the risk population, expenditure with prophylaxis and the budget impact in 2017 to 2018 with official demographic and vaccine coverage data, and aqcuisition of antivirals by SUS. The estimative from 2019 to 2023 was conducted using trigonometric models. RESULTS AND CONCLUSION: The risk population variated from 2.3 to 5.5 millions of individuals and the budget impact variated from 0.74% (2018) and 6.9% (2019).
Referências
Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Ciência e Tecnologia. Diretrizes metodológicas: análise de impacto orçamentário - manual para o Sistema de Saúde do Brasil 2012

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2019 Revista dos Trabalhos de Iniciação Científica da UNICAMP
